ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Noninvasive Evaluation of CD20 Expression Using
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
Clinical PET Imaging Evaluation of 68Ga-BC1 Probe in Multiple Myeloma
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Molecular imaging in gastric cancer: state-of-the-art techniques and emerging opportunities.Journal of translational medicine · 2026Review
- Noninvasive Evaluation of Trop2 Expression UsingMolecular pharmaceutics · 2025Article
- Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies.World journal of clinical oncology · 2025Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer.Cell reports. Physical science · 2025Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [Molecular pharmaceutics · 2025Article
- [American journal of nuclear medicine and molecular imaging · 2025Article
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Theranostic role ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- Molecular Imaging of Melanoma VEGF-expressing Tumors through [Anti-cancer agents in medicinal chemistry · 2024Article
- CD146-targeted nuclear medicine imaging in cancer: state of the art.View (Beijing, China) · 2023Article
- Comment on: "Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors".Journal of pharmaceutical analysis · 2023Article
- Theranostic application ofEuropean journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
CD20-overexpressed non-Hodgkin lymphoma typically indicates progressive malignancy. Obinutuzumab is a next-generation Food and Drug Administration-approved humanized monoclonal antibody that targets CD20. Previous studies with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.